205 related articles for article (PubMed ID: 22782463)
1. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Yamaguchi K; Sawaki A; Doi T; Satoh T; Yamada Y; Omuro Y; Nishina T; Boku N; Chin K; Hamamoto Y; Takiuchi H; Komatsu Y; Saji S; Koizumi W; Miyata Y; Sato A; Baba E; Tamura T; Abe T; Ohtsu A
Gastric Cancer; 2013 Apr; 16(2):175-82. PubMed ID: 22782463
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Sawaki A; Ohashi Y; Omuro Y; Satoh T; Hamamoto Y; Boku N; Miyata Y; Takiuchi H; Yamaguchi K; Sasaki Y; Nishina T; Satoh A; Baba E; Tamura T; Abe T; Hatake K; Ohtsu A
Gastric Cancer; 2012 Jul; 15(3):313-22. PubMed ID: 22179434
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Shen L; Li J; Xu J; Pan H; Dai G; Qin S; Wang L; Wang J; Yang Z; Shu Y; Xu R; Chen L; Liu Y; Yu S; Bu L; Piao Y
Gastric Cancer; 2015 Jan; 18(1):168-76. PubMed ID: 24557418
[TBL] [Abstract][Full Text] [Related]
4. A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Shitara K; Sawaki A; Matsuo K; Kondo C; Takahari D; Ura T; Tajika M; Niwa Y; Muro K
Int J Clin Oncol; 2013 Jun; 18(3):539-46. PubMed ID: 22552360
[TBL] [Abstract][Full Text] [Related]
5. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
Ter Veer E; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Int J Cancer; 2018 Jul; 143(2):438-448. PubMed ID: 29451302
[TBL] [Abstract][Full Text] [Related]
6. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
Satoh T; Omuro Y; Sasaki Y; Hamamoto Y; Boku N; Tamura T; Ohtsu A
Cancer Chemother Pharmacol; 2012 Apr; 69(4):949-55. PubMed ID: 22116464
[TBL] [Abstract][Full Text] [Related]
8. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
Satake H; Iwatsuki M; Uenosono Y; Shiraishi T; Tanioka H; Saeki H; Sugimachi K; Kitagawa D; Shimokawa M; Oki E; Emi Y; Kakeji Y; Tsuji A; Akagi Y; Natsugoe S; Baba H; Maehara Y;
Cancer Chemother Pharmacol; 2017 Jan; 79(1):147-153. PubMed ID: 27942930
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
[TBL] [Abstract][Full Text] [Related]
12. [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Murata Y; Matsuura T; Kanoshima K; Kuwabara H; Fuyuki A; Tomeno W; Taniguchi R; Uchiyama T; Kuriyama H; Hata Y
Gan To Kagaku Ryoho; 2013 Jul; 40(7):933-6. PubMed ID: 23863740
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
[TBL] [Abstract][Full Text] [Related]
15. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Moehler M; Kanzler S; Geissler M; Raedle J; Ebert MP; Daum S; Flieger D; Seufferlein T; Galle PR; Hoehler T;
Ann Oncol; 2010 Jan; 21(1):71-7. PubMed ID: 19605504
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
Zhu B; Wu JR; Zhou XP
Medicine (Baltimore); 2015 Aug; 94(34):e1428. PubMed ID: 26313797
[TBL] [Abstract][Full Text] [Related]
17. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
18. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial.
Shitara K; Hara H; Yoshikawa T; Fujitani K; Nishina T; Hosokawa A; Asakawa T; Kawakami S; Muro K
Int J Clin Oncol; 2020 Feb; 25(2):301-311. PubMed ID: 31620931
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Ohtsu A; Shah MA; Van Cutsem E; Rha SY; Sawaki A; Park SR; Lim HY; Yamada Y; Wu J; Langer B; Starnawski M; Kang YK
J Clin Oncol; 2011 Oct; 29(30):3968-76. PubMed ID: 21844504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
